<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996839</url>
  </required_header>
  <id_info>
    <org_study_id>842</org_study_id>
    <nct_id>NCT01996839</nct_id>
  </id_info>
  <brief_title>Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</brief_title>
  <official_title>Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate
      ophthalmic gel, 0.38% (BID and TID) for the treatment of postoperative inflammation and pain
      following cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Resolution of AC Cells</measure>
    <time_frame>Visit 5 (Postoperative day 8)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants with complete resolution of anterior chamber (AC) cells (cell score = 0) in the study eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Visit 5 (Postoperative Day 8)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants with Grade 0 pain in the study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of AC cells</measure>
    <time_frame>At each study visit through Visit 6 (day 15)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants with complete resolution of AC cells (cell score=0) in the study eye at each on-treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>At each study visit through Visit 6 (day 15)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants with Grade 0 pain (no pain) in the study eye at each on-treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of AC Flare</measure>
    <time_frame>At each study visit through Visit 6 (day 15)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants with complete resolution of AC flare in the study eye at each on-treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of AC Cells and Flare</measure>
    <time_frame>At each study visit through Visit 6 (day 15)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants with complete resolution of AC cells and flare in the study eye at each on-treatment visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug Sensation</measure>
    <time_frame>Visit 5 (Postoperative Day 8)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study drug sensation assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Ocular Symptoms</measure>
    <time_frame>At all study visits through Visit 7 (day 18)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ocular symptoms</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">483</enrollment>
  <condition>Inflammation</condition>
  <condition>Pain</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate Gel (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol Etabonate Gel 0.38% administered two times daily (BID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle (BID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate Gel (TID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol Gel 0.38% administered three times daily (TID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle (TID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate Gel (BID)</intervention_name>
    <description>One drop of LE gel instilled into the study eye two times per day (BID) for 14 days</description>
    <arm_group_label>Loteprednol Etabonate Gel (BID)</arm_group_label>
    <other_name>Lotemax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate Gel (TID)</intervention_name>
    <description>One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.</description>
    <arm_group_label>Loteprednol Etabonate Gel (TID)</arm_group_label>
    <other_name>Lotemax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle (BID)</intervention_name>
    <description>One drop of vehicle instilled into the study eye two times per day (BID) for 14 days</description>
    <arm_group_label>Vehicle (BID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle (TID)</intervention_name>
    <description>One drop of vehicle instilled into the study eye three times per day (TID) for 14 days</description>
    <arm_group_label>Vehicle (TID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Visit 1 (Screening Visit)

          -  Be willing and able to comply with all treatment and follow-up/study procedures.

          -  Be a candidate for routine, uncomplicated cataract surgery

        Visit 3 (Postoperative Day 1)

          -  Have undergone routine, uncomplicated cataract surgery (phaco- emulsification with
             posterior chamber IOL implantation, not combined with any other surgery) in the study
             eye.

          -  Have ≥ Grade 2 anterior chamber (AC) cells (6-15 cells) in the study eye.

        Exclusion Criteria:

          -  Have a severe/serious ocular condition or history/presence of chronic generalized
             systemic disease that the Investigator feels might increase the risk to the subject
             or confound the result(s) of the study.

          -  Have known hypersensitivity or contraindication to the study drug(s) or their
             components.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon I Williams, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert P Keaney, MSPH</last_name>
    <phone>949 789 3170</phone>
    <email>robert.keaney@bausch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Madison</city>
        <state>New Jersey</state>
        <zip>07940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>November 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loteprednol etabonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
